Table 1. Characteristics of included studies.
Study | Country | Comparisons | Mean age (years) | Gender(M/F) | Sample size | Duration of follow-up | Positive Helicobacter pylori test (%) |
---|---|---|---|---|---|---|---|
Bytzer15 | Europe* | Rab 10 vs Pla | 47/48 | 180/238 | 418 | 6 months | 36/37 |
FASS16 | USA | Dex 30 vs Dex 60 vs Pla | 47.6/47.5/47.5 | 274/673 | 947 | 1 month | 30.2/28.6/28.9 |
Kahrilas17 | USA | Rab 20 vs Pla | 43.1/44 | 85/176 | 261 | 1 month | 32.6/30.3 |
Kinoshita20 | Japan | Ome 10 vs Ome 20 | 41.7/48.2 | 18/19 | 37 | 1 month | 29.4/30 |
Kinoshita19 | Japan | Rab 5 vs Rab 10 vs Pla | 46.3/46.8/49.7 | 128/157 | 285 | 1 month | 38/42/48 |
Lind21 | Denmark and Sweden | Ome 10 vs Ome 20 vs pla | 49/50/51 | 206/303 | 509 | 1 month | / |
Lind22 | Denmark and Sweden | Ome 10 vs Ome 20 vs pla | 51/52/48 | 179/245 | 424 | 6 months | / |
Miner23 | USA | Rab 10 vs Rab 20 vs Pla | 44.4/45.5/46.1 | 77/126 | 203 | 1 month | 26.6/35.3/39.7 |
Richter24 | USA | Ome 10 vs Ome 20 vs pla | 50/49.5/49.7 | 193/166 | 359 | 1 month | / |
Richter25 L | USA | Lan 15 vs Lan 30 vs Pla | 44.9/45.1/46.3 | 257/363 | 620 | 2 months | 23.9/23.8/13.4 |
Talley26 | Denmark, Finland, Norway and Sweden | Eso 20 vs Pla | 49/49 | 191/151 | 342 | 6 months | 38/33 |
Talley27 | UK | Eso 20 vs Eso 40 vs Pla | 48.4/48/48.2 | 328/393 | 721 | 6 months | 35.8/30.7/39 |
Tan28 | China | Eso 20 vs Pla | 48.5/48.3 | 62/113 | 175 | 2 months | / |
Uemura29 | Japan | Ome 10 vs Ome 20 vs pla | 44.4/43.8/42.4 | 143/138 | 281 | 1 month | 38.5/52.7/45.7 |
Katz18 A | USA | Eso 20 vs Eso 40 vs Pla | 47/47/46 | 143/225 | 368 | 1 month | 37/39/29 |
Katz18 B | USA | Eso 20 vs Eso 40 vs Pla | 46/45/47 | 126/223 | 349 | 1 month | 43/30/38 |
Rab 5: Rabeprazole 5 mg; Rab 10: Rabeprazole 10 mg; Rab 20: Rabeprazole 20 mg; Pla: Placebo; Dex 30: Dexlansoprazole 30 mg; Dex 60: Dexlansoprazole 60 mg; Ome 10: Omeprazole 10 mg; Ome 20: Omeprazole 20 mg; Lan 15: Lansoprazole 15 mg; Lan 30: Lansoprazole 30 mg; Eso 20: Esomeprazole 20 mg; Eso 40: Esomeprazole 40 mg.
*Greece, Italy, the Netherlands, Spain, France, Portugal, Sweden, Denmark, Ireland, Belgium, United Kingdom, Russia, Poland, and Lithuania.